Response to ‘Clinical presentation of terbinafine-induced severe liver injury and the value of laboratory monitoring: a critically appraised topic’

Abstract

We read with interest the article by Kramer et al entitled "Clinical presentation of terbinafine-induced severe liver injury and the value of laboratory monitoring: a critically appraised topic". ¹ We would like to bring to focus our experience in this regard. With increasing concerns of reduced susceptibility to terbinafine² and an upsurge of recalcitrant cutaneous dermatophytoses, dermatologists in India have been using higher doses of terbinafine for cutaneous dermatophytoses, as used in the early literature with this drug (upto 500mg/day in single or divided doses) ³; and for longer periods of time.

This article is protected by copyright. All rights reserved.

http://ift.tt/2zSl0QR